Achieve Life Sciences is a late-stage specialty pharmaceutical company with one asset and one question: whether cytisinicline, a plant-derived nicotine-receptor partial agonist, can win U.S. approval as a treatment for nicotine dependence. The story of fiscal 2026 has been a regulatory test on fast-forward. In September 2025 the Food and Drug Administration accepted the New Drug Application for cytisinicline in smoking cessation and set a PDUFA targeted action date of June 20, 2026. The company had already told investors in April to expect a rejection on manufacturing grounds. When the Complete Response Letter landed on June 20, it was, by the agency's own framing, narrow: the CRL cited outstanding good-manufacturing-practice observations at a former third-party manufacturer and final product labeling that was not complete by the action date. It identified no deficiencies in the clinical efficacy or safety of cytisinicline.
The quarter is best read as a repositioning rather than a disappointment. Management did not wait for the letter; it had already begun moving finished-drug manufacturing to a U.S.-based contract manufacturer, Adare Pharma Solutions, and in April it closed a private placement of $180 million, with up to a further $174 million in warrants exercisable around FDA approval. It rebuilt the commercial, manufacturing, quality, and board leadership. The stated road from here is mechanical: resubmit the NDA in the fourth quarter of 2026, aim for potential approval in the first half of 2027, and launch in the United States. The market has largely accepted that framing. Shares closed at $6.77, near the 52-week high of $7.11 and roughly double the price at which the company raised capital in April.
That is the central tension the report carries forward: a single-asset biotech whose entire value rests on one resubmitted NDA, now funded to a level that covers years of burn, but with the resubmission itself, the FDA's second look, and a live arbitration with its former manufacturer all unresolved. The second quarter also produced a net loss distorted by non-cash warrant accounting - $74.8 million on $18.4 million of operating expense - so the quarter's real cash story is far smaller than the headline. What decides the thesis is whether the resubmission schedules hold, whether the FDA clears cytisinicline in 2027, and whether the manufacturing dispute with Sopharma disrupts either. Those are the clocks the next reports read.